Showing results (341-350 of 392) with videos related to

Sort By:
Pageof 40
The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Blood Advances|December 8, 2025
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOPOnur Cetin, Igor Age Kos, Evi Regitz, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
The New England Journal of Medicine|June 21, 2013
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMichael L Wang, Simon Rule, Peter Martin, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Blood|October 5, 2018
IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomasRabea Wagener, Cristina López, Kortine Kleinheinz, et al.
Cancer Research|October 23, 2021
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic LeukemiaAnat Biran, Shanye Yin, Helene Kretzmer, et al.
Pageof 40